Privia Health Group, Inc. (PRVA) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Privia Health Group, Inc. is a technology-driven, national physician-enablement company operating in 14 markets. The company collaborates with medical groups and health plans to optimize practices and transition providers to value-based care (VBC) models. As of June 30, 2024, the company had 4,504 Implemented Providers and 1.2 million Attributed Lives.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $422,326 | $413,351 | $837,569 | $799,627 |
| Net Income (Attributable to Privia) | $3,467 | $7,274 | $6,451 | $14,598 |
| Operating Income | $5,098 | $6,979 | $5,921 | $13,693 |
| Adjusted EBITDA | $22,023 | $19,312 | $41,945 | $36,176 |
| Cash and Equivalents | $387,352 | $317,945 | $387,352 | $317,945 |
| Operating Cash Flow (YTD) | $1,330 | $(5,777) | $1,330 | $(5,777) |
Liquidity and Debt: The company holds $387.4 million in cash and cash equivalents. It maintains a $125 million senior secured revolving credit facility with Wells Fargo, with no borrowings outstanding as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2.2% QoQ and 4.7% YTD compared to 2023. This was driven by a 19.4% increase in Fee-for-Service (FFS) patient care revenue and growth in implemented providers.
- Revenue Mix Shift: Capitated revenue decreased significantly (34.9% QoQ) due to the renegotiation of at-risk contracts. Approximately 19,800 Attributed Lives were moved from gross capitated revenue to net shared savings revenue effective January 1, 2024, to improve contribution margins.
- Profitability Decline: Net income attributable to Privia decreased 52.3% QoQ and 55.8% YTD. This decline is primarily attributed to a 55.8% increase in stock-based compensation expense ($14.4M in Q2 2024 vs. $9.2M in Q2 2023) and higher tax provisions.
- Operating Expenses: Cost of platform expenses rose 13.8% QoQ due to increased salaries, platform costs, and stock-based compensation. General and administrative expenses increased 7.9% QoQ, largely driven by stock-based compensation.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management continues to focus on expanding the provider base and transitioning markets to VBC. The company entered four new markets in 2023 (Connecticut, Ohio, Washington, South Carolina) which contributed to provider growth.
- Non-GAAP Performance: While GAAP net income declined, Adjusted EBITDA increased 14.0% QoQ and 15.9% YTD, reflecting underlying operational growth and the benefits of contract renegotiations.
- Risks: Key risks include regulatory changes in healthcare, dependence on relationships with medical groups, competition, and the financial impact of compliance with privacy laws. The company also notes reliance on its EMR vendor, athenahealth.
- Guidance: The filing does not provide specific numerical forward-looking guidance for the full year 2024, stating that results for the first half are not indicative of full-year expectations.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the sustainability of the 55% increase in stock-based compensation expense and its effect on future GAAP profitability.
- Contract Renegotiation Benefits: Assess whether the shift from capitated to shared savings revenue models is delivering the expected margin improvements as projected by management.
- Provider Retention: Confirm the 96% provider retention rate and the pace of new provider additions in new markets to validate revenue growth assumptions.
- Cash Flow Conversion: Monitor the conversion of net income to operating cash flow, noting the improvement from negative cash flow in 2023 to positive in 2024.
- Debt Covenants: Review the financial covenants of the $125M Wells Fargo credit facility to ensure continued compliance as the company scales.